Medium Term Plan
The Shionogi Growth Strategy (SGS 2020) outlines our Corporate Mission “Shionogi’s purpose”- Shionogi strives constantly to supply the best possible medicine to protect the health and wellbeing of the patients we serve- on a global basis.
Shionogi is investigating products for the management of diabetic, neuropathic and cancer-related pain.
As a leading maker of drugs to treat infectious diseases, one of our notable achievements was the successful generation of potential new antibiotics targeting multidrug-resistant gram negative bacteria, identified as a major problem worldwide. We have discovered multiple integrase inhibitors for the treatment of HIV and will continue to focus on emerging and re-emerging conditions caused by infectious agents.
Cardiovascular and metabolic diseases
Shionogi has a strong heritage in this area, with key milestones including the invention of Crestor® (rosuvastatin), now marketed in Europe by AstraZeneca. Shionogi currently has products in development for diabetes and hypertension.
We are looking to the future on oncology with early stage products in development for the treatment of bladder, breast, stomach / oesophageal and head and neck cancer.
One of our main focus areas is a potential therapy for post-menopausal vulvar and vaginal atrophy, a condition in which declining oestrogen levels have adversely affected the thickness of vaginal epithelial cells, elasticity, and vaginal secretion.
Allergies / Immunology
We currently have two products in clinical trials for allergic disease and dust mite allergy as well as marketing products for allergic rhinitis and asthma in Japan. Shionogi is also exploring the use of novel target molecules to treat immunological conditions such as psoriasis and dermatitis.
Central nervous system (CNS) diseases
We are interested in the development of novel screening methods to effectively measure synapse functions in the CNS disease area and for ideas of novel drug delivery technologies to cross the blood brain barrier.